SQZ Biotechnologies Company
SQZ was delisted on the 3rd of July, 2023.
44 hedge funds and large institutions have $199M invested in SQZ Biotechnologies Company in 2021 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 20 increasing their positions, 14 reducing their positions, and 7 closing their positions.
43% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 14
25% more capital invested
Capital invested by funds: $159M → $199M (+$39.7M)
10% less funds holding
Funds holding: 49 → 44 (-5)
71% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
+$4.3M |
| 2 |
Temasek Holdings
Singapore
|
+$3.04M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.69M |
| 4 |
MC
Maverick Capital
Dallas,
Texas
|
+$999K |
| 5 |
JP Morgan Chase
New York
|
+$745K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LM
Luminus Management
Houston,
Texas
|
-$5.11M |
| 2 |
Morgan Stanley
New York
|
-$2.14M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$1M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$668K |
| 5 |
JF
Jump Financial
Chicago,
Illinois
|
-$389K |
SQZ Hedge Fund Activity: Q3 2021 in Review
44 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in SQZ Biotechnologies Company (SQZ) for Q3 2021, worth a combined $199M — up 25% from $159M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of SQZ and 2 opened new positions — a net loss of 5 holders — while 14 trimmed existing stakes and 20 added.
The largest buyer was 683 Capital Management, adding an estimated $4.3M. The largest seller was Luminus Management, exiting entirely with an estimated $5.11M sold.
- 44 institutional investors held SQZ Biotechnologies Company (SQZ) as of Q3 2021, down from 49 in Q2 2021.
- Funds reported $199M of SQZ Biotechnologies Company stock for Q3 2021, up 25% quarter-over-quarter.
- 2 funds opened new SQZ Biotechnologies Company positions in Q3 2021 and 7 closed out, a net change of -5 holders.
- The largest SQZ Biotechnologies Company buyer in Q3 2021 was 683 Capital Management, an estimated $4.3M added.
- The largest SQZ Biotechnologies Company seller in Q3 2021 was Luminus Management, an estimated $5.11M sold.
Based on aggregated 13F filings for Q3 2021.